A report by Dr Barbara drafted the relevant protocols for the provision of testing kits and to undertake anti-HCV testing on samples for discussion at a further meeting with Ortho on 29 March 1989. Read more about A report by Dr Barbara drafted the relevant protocols for the provision of testing kits and to undertake anti-HCV testing on samples for discussion at a further meeting with Ortho on 29 March 1989.
Dr Gunson wrote to Dr M E Smith to agree to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing relating to HCV. Read more about Dr Gunson wrote to Dr M E Smith to agree to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing relating to HCV.
There was HCV testing under development and Dr Gunson and Dr Barbara were told that clinical trials would soon begin. They agreed to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing. Read more about There was HCV testing under development and Dr Gunson and Dr Barbara were told that clinical trials would soon begin. They agreed to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing.
John Canavan stated that reference to the HCV screening being marginal in terms of cost benefit by the Department of Health related to the economic cost-benefit and not the public health benefit. Read more about John Canavan stated that reference to the HCV screening being marginal in terms of cost benefit by the Department of Health related to the economic cost-benefit and not the public health benefit.
There was a shift in the NHS funding model which took place in 1991, from centralised and area funding provided by the Department of Health and regional health authorities, to an internal market system. Read more about There was a shift in the NHS funding model which took place in 1991, from centralised and area funding provided by the Department of Health and regional health authorities, to an internal market system.
It was the preference, but not a formal requirement, that the test be licensed in the US by the FDA before being adopted for use in the UK. Read more about It was the preference, but not a formal requirement, that the test be licensed in the US by the FDA before being adopted for use in the UK.
Dr Rejman expected the PHLS would soon publish the results of their experience of Chiron testing of presumed non-A non-B Hepatitis samples, and would be making a recommendation for use of this test in this publication in September 1989. Read more about Dr Rejman expected the PHLS would soon publish the results of their experience of Chiron testing of presumed non-A non-B Hepatitis samples, and would be making a recommendation for use of this test in this publication in September 1989.
Dr Perry recalled that Dr Metters was concerned that all the details had to be correct before the bigger in principle decision could be made on HCV screening. Read more about Dr Perry recalled that Dr Metters was concerned that all the details had to be correct before the bigger in principle decision could be made on HCV screening.
Dr Huw Lloyd's evidence to the Inquiry was that Dr Gunson never communicated to him that there was a funding reason holding up the commencement of screening. Read more about Dr Huw Lloyd's evidence to the Inquiry was that Dr Gunson never communicated to him that there was a funding reason holding up the commencement of screening.
Dr Boulton told the Inquiry that he felt there was an ethical need to introduce Hepatitis C screening at the earliest opportunity, and that it was shameful that "the UK was among the latest countries in Europe" to introduce testing. Read more about Dr Boulton told the Inquiry that he felt there was an ethical need to introduce Hepatitis C screening at the earliest opportunity, and that it was shameful that "the UK was among the latest countries in Europe" to introduce testing.